X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6222,658-   
Low Rs4582,309-   
Sales per share (Unadj.) Rs181.91,525.2-  
Earnings per share (Unadj.) Rs12.995.3-  
Cash flow per share (Unadj.) Rs29.3218.6-  
Dividends per share (Unadj.) Rs2.0083.41-  
Dividend yield (eoy) %0.43.4 11.0%  
Book value per share (Unadj.) Rs155.71,694.2-  
Shares outstanding (eoy) m804.51848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.6 182.4%   
Avg P/E ratio x42.026.1 161.0%  
P/CF ratio (eoy) x18.411.4 162.2%  
Price / Book Value ratio x3.51.5 236.7%  
Dividend payout %15.587.5 17.8%   
Avg Mkt Cap Rs m434,5162,105,694 20.6%   
No. of employees `00023.044.9 51.3%   
Total wages/salary Rs m26,3380-   
Avg. sales/employee Rs Th6,349.128,777.2 22.1%   
Avg. wages/employee Rs Th1,143.00-   
Avg. net profit/employee Rs Th449.31,797.7 25.0%   
INCOME DATA
Net Sales Rs m146,3021,293,392 11.3%  
Other income Rs m2,2870-   
Total revenues Rs m148,5891,293,392 11.5%   
Gross profit Rs m24,758354,196 7.0%  
Depreciation Rs m13,229104,546 12.7%   
Interest Rs m1,59425,404 6.3%   
Profit before tax Rs m12,222224,246 5.5%   
Minority Interest Rs m01,019 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-147,205 0.0%   
Tax Rs m1,798-2,738 -65.7%   
Profit after tax Rs m10,35480,797 12.8%  
Gross profit margin %16.927.4 61.8%  
Effective tax rate %14.7-1.2 -1,204.7%   
Net profit margin %7.16.2 113.3%  
BALANCE SHEET DATA
Current assets Rs m87,370873,552 10.0%   
Current liabilities Rs m33,081761,812 4.3%   
Net working cap to sales %37.18.6 429.5%  
Current ratio x2.61.1 230.3%  
Inventory Days Days8791 95.8%  
Debtors Days Days6296 65.0%  
Net fixed assets Rs m111,567422,450 26.4%   
Share capital Rs m1,6093,184 50.5%   
"Free" reserves Rs m123,6450-   
Net worth Rs m125,2541,436,714 8.7%   
Long term debt Rs m36,454661,340 5.5%   
Total assets Rs m209,5322,955,816 7.1%  
Interest coverage x8.79.8 88.2%   
Debt to equity ratio x0.30.5 63.2%  
Sales to assets ratio x0.70.4 159.6%   
Return on assets %5.73.6 158.7%  
Return on equity %8.35.6 147.0%  
Return on capital %8.54.9 172.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Net fx Rs m33,3880-   
CASH FLOW
From Operations Rs m23,824206,100 11.6%  
From Investments Rs m-13,127-73,029 18.0%  
From Financial Activity Rs m-13,239-247,231 5.4%  
Net Cashflow Rs m-2,478-114,160 2.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare CIPLA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare CIPLA With: TORRENT PHARMA  PANACEA BIOTECH  J.B.CHEMICALS  DR. REDDYS LAB  WOCKHARDT LTD.  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views On News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 16, 2018 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS